PRLD
NASDAQ
$4.06
Prelude Therapeutics Inc (PRLD)
Prelude Therapeutics Incorporated, a precision clinical-stage oncology company, focuses on the discovery and development of small molecule therapies optimized to target key drivers in cancers. The company is headquartered in Wilmington, Delaware.
Sector:
Healthcare
Industry:
Biotechnology
Strong Buy
Target: $8 (+97.04%)
Market Cap
$368M
Free Cash Flow Yield
-11.89%
Beta (5Y)
1.85
Price Chart
Valuation
Market Cap$368M
P/S21.25
P/B5.81
Profitability
Total Revenue (TTM)$17M
Gross Profit (TTM)$17M
EBITDA-$82M
Operating Margin-309.5%
EPS-$1.07
Financial Health
Free Cash Flow Yield-11.89%
Growth & Risk
FCF 5Y CAGR-4.08%
Beta (5Y)1.85
Sharpe Ratio1.56